Manufacturer profileMAXIGEN BIOTECH INC.
TaiwanTaiwan, Province of China20 products registeredSep 14, 2017 – Aug 01, 2024
VerifiedTFDA · Taiwan Food and Drug Administration registry
20
Total products
19
Product types
19
Active products
Aug 2024
Latest registration
Company details
- Address
- 桃園市龜山區文化里科技一路88號（2、3樓）及88號4樓（4、5樓）
Regulatory footprint
Search MAXIGEN BIOTECH INC. across other regulatory registries
Thailand
European Union
Colombia
South Korea
Canada
EcuadorRecent registrations
Latest 5 products registered by this manufacturer
Most popular products
Products with most registrations
Authorized representatives
Taiwan authorized representatives for this manufacturer
Recent registered products
Most recent products (showing top 20)
Miquelon collagen matrix
Registered: Aug 01, 2024 • Expires: Sep 25, 2028
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Nasal fixation (bacterium)
Registered: Mar 25, 2024 • Expires: Mar 25, 2029
- Risk Class
- Class 1
- AR
- MAXIGEN BIOTECH INC.
Sedengling (with Lidocaine)
Registered: Mar 19, 2024 • Expires: Jun 22, 2028
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Silken-Aged Radiant Skin Filler
Registered: Feb 23, 2023 • Expires: Apr 19, 2028
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Silkenling Radiant Skin Filler
Registered: Jan 04, 2023 • Expires: Apr 25, 2028
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Silkenling Fengyan skin filler
Registered: Oct 31, 2022 • Expires: Apr 08, 2029
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Joy long-acting intra-articular injection
Registered: Aug 23, 2022 • Expires: Aug 23, 2027
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
BIOPORT PLUS 1.5% Intra-articular Injection
Registered: Jul 26, 2022 • Expires: Jun 30, 2028
- Risk Class
- Class 3
- Type
- MD
- AR
- MAXIGEN BIOTECH INC.
BIOPORT CROSSLINK 2.0% Intra-articular Injection
Registered: Jul 26, 2022 • Expires: Oct 13, 2026
- Risk Class
- Class 3
- Type
- MD
- AR
- MAXIGEN BIOTECH INC.
Intra-articular injection
Registered: Dec 24, 2021 • Expires: Dec 24, 2026
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Water-based wound and burn coverings (sterilized)
Registered: May 24, 2021 • Expires: May 24, 2026
- Risk Class
- Class 1
- AR
- MAXIGEN BIOTECH INC.
Vivid Ophthalmic viscoelastic agent
Registered: Dec 23, 2020 • Expires: Feb 04, 2030
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Furuim bone fills particles
Registered: Oct 28, 2019 • Expires: Nov 05, 2029
- Risk Class
- Class 2
- AR
- MAXIGEN BIOTECH INC.
Intra-articular injection
Registered: Oct 10, 2019 • Expires: Aug 22, 2026
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Halleiro contains lidocaine
Registered: Jan 25, 2019 • Expires: Jul 10, 2028
- Risk Class
- Class 3
- AR
- ORIENT EUROPHARMA CO., LTD.
Hallerun contains lidocaine
Registered: Jan 25, 2019 • Expires: Jun 22, 2028
- Risk Class
- Class 3
- AR
- ORIENT EUROPHARMA CO., LTD.
Dermedon (with lidocaine)
Registered: Jul 10, 2018 • Expires: Jul 10, 2028
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Furome (including lidocaine)
Registered: Jun 22, 2018 • Expires: Jun 22, 2028
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
Fuqiao honey skin filler
Registered: Apr 19, 2018 • Expires: Apr 19, 2028
- Risk Class
- Class 3
- AR
- MAXIGEN BIOTECH INC.
“BioTai” Plus Intra-articular Injection
Registered: Sep 14, 2017 • Expires: Aug 22, 2021
Cancelled
- Risk Class
- Class 3
- Type
- MD
- AR
- MAXIGEN BIOTECH INC.
About this profile
Explore comprehensive manufacturer profile for MAXIGEN BIOTECH INC. based in Taiwan, Province of China through Pure Global AI's free Taiwan medical device database. This manufacturer has 20 products registered in Taiwan across 19 unique product categories. Their regulatory history spans from Sep 14, 2017 to Aug 01, 2024.
This page provides detailed insights including 5 recent product registrations, 5 most popular products with Intra-articular injection having 2 registrations, and 2 authorized representatives including MAXIGEN BIOTECH INC.. Pure Global AI offers free access to Taiwan's medical device database, enabling global MedTech companies to analyze market dynamics and identify opportunities.